How Does Rezdiffra (Resmetirom) Work? Mechanism of Action Explained in Plain English

Rezdiffra (resmetirom) works in a fundamentally different way from most medications you may have taken. Rather than blocking a receptor or killing bacteria, it activates a specific switch inside liver cells that tells them to burn fat more efficiently. The result is less fat in the liver, less inflammation, and less scarring over time.

Understanding how Rezdiffra works can help you feel more confident about your treatment and better understand why certain monitoring tests and drug interactions matter. Let's break it down.

The Problem: Why Fat Builds Up in the Liver in MASH

In MASH (metabolic dysfunction-associated steatohepatitis), fat accumulates inside liver cells — a condition called steatosis. This happens when the liver receives more fat and sugar than it can process, often because of obesity, insulin resistance, or high-fat diet. The excess fat triggers inflammation. Over time, that chronic inflammation damages liver cells and causes the liver to lay down scar tissue (fibrosis). If fibrosis progresses far enough, it becomes cirrhosis — and eventually, liver failure.

Rezdiffra's mechanism of action targets this fat accumulation at its root — inside liver cells — before it has a chance to cause more damage.

What Is THR-β and Why Does It Matter?

The key to Rezdiffra's mechanism is a receptor called Thyroid Hormone Receptor-beta (THR-β). Receptors are like locks inside cells — they only open (activate) when the right key comes along. THR-β is the dominant thyroid hormone receptor in the liver. When thyroid hormone binds to it, the liver ramps up fat burning and reduces fat synthesis.

Here's the problem with naturally occurring thyroid hormone: it doesn't just work in the liver. Thyroid hormones act throughout the body — increasing heart rate, affecting bone density, and more. If you just gave someone extra thyroid hormone to help their liver, you'd cause serious cardiovascular and bone side effects.

How Rezdiffra Targets Only the Liver

Rezdiffra was engineered to be "liver-directed" and THR-β selective. This means two things:

Liver-directed: After oral absorption, Rezdiffra is concentrated in the liver. Very little reaches the heart or other organs at significant levels.

THR-β selective: It preferentially activates the beta subtype of the thyroid hormone receptor (THR-β), which is the predominant form in the liver. It has much weaker activity at THR-α, the receptor subtype found primarily in the heart and which drives cardiovascular thyroid effects.

In clinical terms, Rezdiffra functions like a "precision key" — it opens the fat-burning switch in the liver without turning on the cardiovascular effects that would otherwise be triggered by thyroid hormone.

What Happens Inside the Liver When Rezdiffra Is Active?

When resmetirom activates THR-β inside liver cells, it triggers a cascade of metabolic changes:

Increased beta-oxidation: Liver cells ramp up their fat-burning machinery, breaking down more fatty acids for energy.

Reduced fat synthesis (lipogenesis): Liver cells make less new fat.

Lower intrahepatic triglycerides: Less fat stored in liver cells.

Reduced liver inflammation: With less fat stress, inflammatory signaling decreases.

Improved fibrosis biomarkers: Over time, as inflammation decreases, fibrosis markers improve.

The Bonus: Cardiovascular Benefits

Because THR-β activation also affects cholesterol metabolism, Rezdiffra reduces blood levels of atherogenic lipids — including LDL cholesterol and lipoprotein(a), a particularly cardiovascular-risky form of cholesterol. This is a meaningful bonus for MASH patients, who have elevated baseline cardiovascular risk due to their metabolic profile (obesity, type 2 diabetes, dyslipidemia).

How Is Rezdiffra Different From Other MASH Treatments?

Compare Rezdiffra's mechanism to the other FDA-approved MASH treatment:

Rezdiffra (resmetirom): Acts directly on liver cells via THR-β to reduce fat accumulation and inflammation. Liver-directed, oral daily tablet. No weight loss effect.

Semaglutide (Wegovy): A GLP-1 receptor agonist that reduces caloric intake and promotes weight loss, which secondarily reduces liver fat and inflammation. Weekly injection. Significant weight loss as a primary effect.

The two drugs work through completely different pathways, which is why researchers are studying them in combination — their mechanisms may be additive or synergistic.

How Quickly Does Rezdiffra Start Working?

Resmetirom reaches steady-state drug levels in the blood within 3–6 days of starting treatment. Liver enzyme improvements (reductions in ALT and AST) are typically detectable by month 3. Liver fat reduction on MRI-PDFF imaging can be seen within 12–24 weeks. Histological improvement (visible on liver biopsy) was measured at 12 months in the MAESTRO-NASH trial.

Your hepatologist may order an MRI-PDFF scan around 12–24 weeks to assess your early response. A ≥30% reduction in MRI-PDFF is a strong indicator that the drug is working and predicts better long-term histologic outcomes.

Want to Learn More?

For a comprehensive overview of Rezdiffra including who qualifies, dosing details, and how to access it, see: What Is Rezdiffra? Uses, Dosage, and What You Need to Know. If you're struggling to fill your Rezdiffra prescription, medfinder can help you find which pharmacies near you carry it.